Gal Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Galanin is a 30-amino acid neuropeptide encoded by the GAL gene on chromosome 11q13.2 that acts as a widespread neuromodulator in the central and peripheral nervous systems[1]. Galanin is unique among neuropeptides in its ability to co-exist with classical neurotransmitters, particularly acetylcholine and norepinephrine, allowing it to fine-tune neuronal circuits involved in cognition, mood, pain processing, and neuroprotection.
The GAL gene encodes preprogalanin, which is processed to galanin (1-29) and galanin message-associated peptide (GMAP). Galanin is widely distributed in the brain and peripheral tissues[2].
Galanin shows widespread expression:
| Brain Region | Expression Level | Functional Significance |
|---|---|---|
| Hypothalamus | Very High | Energy homeostasis |
| Hippocampus | High | Memory, plasticity |
| Amygdala | High | Emotional processing |
| Dorsal Raphe | High | Mood, serotonin interaction |
| Locus Coeruleus | High | Arousal, attention |
| Spinal Cord | High | Pain modulation |
| Cortex | Moderate | Cognition |
Galanin signals through three G-protein coupled receptors (GALR1, GALR2, GALR3), each with unique signaling properties[3]:
Galanin is upregulated in AD brains, particularly in the basal forebrain[4]. This upregulation may represent a compensatory neuroprotective response or contribute to cholinergic dysfunction. Galaninergic drugs are being explored for cognitive enhancement.
Galanin co-localizes with dopaminergic neurons and may modulate their function. Changes in galanin expression are observed in PD brains, potentially affecting motor and non-motor symptoms.
Galanin signaling is implicated in mood disorders. GALR3 antagonists show potential antidepressant effects in preclinical models.
Galanin has anticonvulsant properties through inhibition of excitatory neurotransmission. Galanin agonists may have therapeutic potential.
Galanin modulates pain transmission in the spinal cord. The peptide has both pro-nociceptive and anti-nociceptive effects depending on receptor subtype and location.
| Drug/Compound | Target | Development Stage | Application |
|---|---|---|---|
| Galanin agonists | GALR1/2 | Research | Epilepsy, analgesia |
| Galanin antagonists | GALR3 | Preclinical | Depression, anxiety |
| Galnon | GALR1/2 agonist | Research | Cognitive enhancement |
| M617 | GALR1 agonist | Research | Pain, cognition |
Galanin system modulation offers potential for:
The study of Gal Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tatemoto K, Rökaeus A, Jörnvall H, McDonald TJ, Mutt V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Letters. 1983;164(1):124-128. PMID:6198235.
Crawley JN. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. Journal of Molecular Neuroscience. 2018;66(4):546-555. PMID:30341625.
Liu HX, Hökfelt T. The galaninergic system in Alzheimer's disease. Neurobiology of Disease. 2019;130:104527. PMID:31295584.
Counts SE, Perez SE, Kahl J, et al. Galanin in Alzheimer disease. Molecular Interventions. 2008;8(1):17-24. PMID:18332267.
Holmes A, Kinney JW, Wrenn CC, et al. Galanin transgenic mice: galanin and behavior. Cellular and Molecular Life Sciences. 2008;65(12):1872-1883. PMID:18500646.
Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor signaling, neurofunctions, and therapeutic approaches. Pharmacology & Therapeutics. 2022;232:107995. PMID:34606821.
Mazarati A, Langel U, Hökfelt T. Galanin and epilepsy. Cellular and Molecular Life Sciences. 2018;75(11):1915-1922. PMID:29500593.
Kuteeva E, Hökfelt T, Wardi T, Ogren SO. Galanin, galanin receptor subtypes and depression-like behaviour. Expert Opinion on Therapeutic Targets. 2008;12(6):761-769. PMID:18555279.